- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in combination with carboplatin and etoposide
- Combination Product
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–453
of 453
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor
- Interventions
- Durvalumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 12
- States / cities
- Fullerton, California • Washington D.C., District of Columbia • Augusta, Georgia + 9 more
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy
- Drug · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 712 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 31
- States / cities
- Orange, California • Santa Monica, California • New Haven, Connecticut + 28 more
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 4
- States / cities
- Newark, Delaware • Minneapolis, Minnesota • Reno, Nevada + 1 more
- Conditions
- Larynx, Lip, Oral Cancer, Digestive Organs--Diseases
- Interventions
- Durvalumab, Intensity Modulated Radiotherapy Treatments
- Drug · Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Chapel Hill, North Carolina • Charleston, South Carolina
- Conditions
- Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
- Interventions
- Cabozantinib, Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- Anwaar Saeed
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 2
- States / cities
- Westwood, Kansas • Pittsburgh, Pennsylvania
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Interventions
- Durvalumab, Tremelimumab
- Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery, Tremelimumab
- Biological · Other · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Durvalumab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 9 more
- Conditions
- Colorectal Neoplasms, Breast Neoplasms
- Interventions
- Olaparib, Cediranib, Durvalumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- nab-paclitaxel IV, CC-486, Duravalumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 9
- States / cities
- San Francisco, California • New Britain, Connecticut • Athens, Georgia + 6 more
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Mismatch Repair Deficiency, Refractory Colorectal Carcinoma, Refractory Lung Carcinoma, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Danvatirsen, Durvalumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced/Metastatic NSCLC
- Interventions
- Immunotherapy - PD-1 Blocker
- Drug
- Lead sponsor
- Liza Villaruz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Breast Cancer, Triple Negative Breast Cancer
- Interventions
- Durvalumab, Radiation Therapy, Carboplatin, Paclitaxel
- Drug · Radiation
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 13
- States / cities
- Duarte, California • Newport Beach, California • Orange, California + 10 more
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Interventions
- Carboplatin, Cisplatin, Computed Tomography, Durvalumab, Etoposide, Image Guided Radiation Therapy, Nab-paclitaxel, Osimertinib, Paclitaxel, Pemetrexed, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 476
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 357 more
- Conditions
- Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
- Interventions
- Tarlatamab, Durvalumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Los Angeles, California • New Haven, Connecticut + 32 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Tremelimumab, Durvalumab, Transarterial Chemoembolization (TACE), Lenvatinib
- Drug · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 9 more
- Conditions
- Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy
- Interventions
- Carboplatin/Cisplatin -Etoposide - Atezolizumab
- Drug
- Lead sponsor
- Oncology Center of Biochemical Education And Research
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Pumitamig, Durvalumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2034
- U.S. locations
- 38
- States / cities
- Daphne, Alabama • Golden, Colorado • Newark, Delaware + 32 more
- Conditions
- Non-Small Cell Lung Cancer NSCLC
- Interventions
- durvalumab
- Drug
- Lead sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Dallas, Texas